NEW YORK, May 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
--
Vertex Pharmaceuticals Incorporated Analyst Notes
On May 1, 2014, Vertex Pharmaceuticals Incorporated (Vertex) announced that a 28-day Phase 2 study of the treatment with the combination of VX-661 and KALYDECO® (ivacaftor) for four weeks, showed statistically significant improvements in lung function (FEV1) in people with both the F508del mutation and G551D mutation who were already taking KALYDECO. According to the Company, VX-661 was added to patients with ongoing KALYDECO treatment for four weeks to evaluate the safety of the combination regimen as well as the effect on lung function, sweat chloride and other measures. The Company stated that treatment with a combination of KALYDECO and VX-661 for 28 days resulted in a mean within-group absolute improvement in lung function of 4.6 percentage points (p=0.012), a mean within-group relative improvement in lung function of 7.3% (p=0.012) and a mean reduction in sweat chloride of -7.02 mmol/L (p=0.053) through the end of treatment. The full analyst notes on Vertex are available to download free of charge at:
http://www.analystsreview.com/2188-VRTX-08May2014.pdf
--
PerkinElmer Inc. Analyst Notes
On May 1, 2014, PerkinElmer Inc. (PerkinElmer) reported that it will present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 9:20 a.m. PDT, at the Encore at Wynn in Las Vegas. According to PerkinElmer, its Chairman and CEO, Robert F. Friel, will give an overview of the Company and its strategic objectives. The Company informed that a live audio webcast of the presentation will be made available on its website under the investor section. Additionally, a replay of the presentation will be available on the Company's website for 2 weeks. The full analyst notes on PerkinElmer are available to download free of charge at:
http://www.analystsreview.com/2188-PKI-08May2014.pdf
--
PAREXEL International Corporation Analyst Notes
On April 29, 2014, PAREXEL International Corporation (PAREXEL) reported its Q3 FY 2014 financial results (period ended March 31, 2014). Total revenues went up by 10.4% YoY to $577.9 million. Net income was $34.7 million or $0.60 per diluted share, compared to $29.5 million or $0.50 per diluted share in Q3 FY 2013. PAREXEL Chairman and CEO, Josef H. von Rickenbach, remarked, "In the third quarter, we delivered revenue in line with guidance, solid operational improvements, earnings that exceeded our expectations, and positive new business results. Our third quarter GAAP operating margin of 10.6% is an all-time record for the Company. We are pleased that the productivity and efficiency-related investments we have made, particularly in the Clinical Research Services business, have continued to pay off." For Q4 FY 2014, the Company expects revenue to be within $507 million to $513 million and EPS to be $0.59 to $0.63. The full analyst notes on PAREXEL are available to download free of charge at:
http://www.analystsreview.com/2188-PRXL-08May2014.pdf
--
ACADIA Pharmaceuticals, Inc. Analyst Notes
On May 1, 2014, ACADIA Pharmaceuticals, Inc. (ACADIA Pharmaceuticals) announced that it will present at the following upcoming conferences: The Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 10:40 a.m. ET, in Boston; and The Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 9:20 a.m. PT, in Las Vegas. According to the Company, live webcasts of the presentations will be made accessible on the Company's website under the investors section whereas an archived recording will be available on the website for two weeks following the completion of the applicable presentation. The full analyst notes on ACADIA Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/2188-ACAD-08May2014.pdf
--
Arena Pharmaceuticals, Inc. Analyst Notes
On May 5, 2014, Arena Pharmaceuticals, Inc. (Arena Pharmaceuticals) announced that it will provide a corporate update and report Q1 2014 financial results after the NASDAQ Global Select Market closes on May 12, 2014. The Company informed that on the same day it will also host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT). Arena Pharmaceuticals stated that the call will be webcast live under the Investor Relations section of the Company website, and will also be archived there for 30 days following the call. The full analyst notes on Arena Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/2188-ARNA-08May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
